top of page
News, Events and Updates
Search
Anavex Reports ANAVEX 2-73 Blocks Tau and Amyloid-Beta Proteins in a Preclinical Model of AD
Nov 4, 2013
Anavex to Present Data for ANAVEX 2-73 at Society for Neuroscience 2013 Annual Meeting
Oct 29, 2013
Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73
Oct 22, 2013
Anavex Comments on Newly Released World Alzheimer Report 2013
Sep 23, 2013
Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
Sep 3, 2013
Anavex CEO Writes Letter to Shareholders
Aug 15, 2013
Anavex Raises $2.6M in Private Placement and Conversion of Liabilities, Enters into $10M Financing
Jul 8, 2013
Anavex Invited to File Funding Application for Phase 2a Clinical Trial of ANAVEX 2-73
May 6, 2013
Anavex Comments on FDA Plan to Expedite Approval of New Alzheimer's Drugs
Mar 18, 2013
ANAVEX 2-73 Restores Mitochondrial Functionality, Clocks Cell Death and Oxidative Stress
Mar 12, 2013
Mitochondrial Protection in Mouse Hippocampus against Aβ25-35 Toxicity is Induced by the Novel...
Mar 6, 2013
40
41
42
43
44
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
